Texas Oncology

Sorting 2 by

Accepting patients

Teclistamab

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2

Not yet accepting

Selinexor

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Learn more
  • SINE
  • Phase 2